FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer
San Antonio Breast Cancer Symposium
Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone
Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target
Pharmacology and Therapeutics
Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients
Precison: Lung Cancer R&D Summit
Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640
EORTC-NCI-AACR International Conference
